OPKO Health — Third Quarter 2026 Earnings Summary

OPKO Health reported third-quarter 2026 financial results, announcing a $65.4 million revenue increase to $65.4 million driven by higher royalties from Eli Lilly and growth in international operations. The company entered into an agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash plus up to $150 million in contingent payments, classifying BioReference as a discontinued operation. OPKO also expanded its financing with HealthCare Royalty by issuing an additional $125 million in senior secured royalty notes and advanced clinical trials for its investigational drugs, including the first dosing of OPK-8801001 for acromegaly and enrollment completion for MDX2301 against SARS-CoV-2 variants.